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ABSTRACT Zika virus (ZIKV), a mosquito-transmitted flavivirus responsible for spo-
radic outbreaks of mild and febrile illness in Africa and Asia, reemerged in the last
decade causing serious human diseases, including microcephaly, congenital malfor-
mations, and Guillain-Barré syndrome. Although genomic and phylogenetic analyses
suggest that genetic evolution may have led to the enhanced virulence of ZIKV, ex-
perimental evidence supporting the role of specific genetic changes in virulence is
currently lacking. One sequence motif, VNDT, containing an N-linked glycosylation
site in the envelope (E) protein, is polymorphic; it is absent in many of the African
isolates but present in all isolates from the recent outbreaks. In the present study,
we investigated the roles of this sequence motif and glycosylation of the E protein
in the pathogenicity of ZIKV. We first constructed a stable full-length cDNA clone of
ZIKV in a novel linear vector from which infectious virus was recovered. The recom-
binant ZIKV generated from the infectious clone, which contains the VNDT motif, is
highly pathogenic and causes lethality in a mouse model. In contrast, recombinant
viruses from which the VNDT motif is deleted or in which the N-linked glycosylation
site is mutated by single-amino-acid substitution are highly attenuated and nonle-
thal. The mutant viruses replicate poorly in the brains of infected mice when inocu-
lated subcutaneously but replicate well following intracranial inoculation. Our find-
ings provide the first evidence that N-linked glycosylation of the E protein is an
important determinant of ZIKV virulence and neuroinvasion.
IMPORTANCE The recent emergence of Zika virus (ZIKV) in the Americas has caused
major worldwide public health concern. The virus appears to have gained significant
pathogenicity, causing serious human diseases, including microcephaly and
Guillain-Barré syndrome. The factors responsible for the emergence of patho-
genic ZIKV are not understood at this time, although genetic changes have been
shown to facilitate virus transmission. All isolates from the recent outbreaks con-
tain an N-linked glycosylation site within the viral envelope (E) protein, whereas
many isolates of the African lineage virus lack this site. To elucidate the func-
tional significance of glycosylation in ZIKV pathogenicity, recombinant ZIKVs
from infectious clones with or without the glycan on the E protein were gener-
ated. ZIKVs lacking the glycan were highly attenuated for the ability to cause
mortality in a mouse model and were severely compromised for neuroinvasion.
Our studies suggest glycosylation of the E protein is an important factor contrib-
uting to ZIKV pathogenicity.
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Following isolation of Zika virus (ZIKV) in 1947 from a rhesus monkey in Uganda (1),only a few cases of human infections were reported in Africa and Asia in the next
60 years (2–4). However, the virus reemerged during the last decade, causing outbreaks
on Yap Island of the Federated States of Micronesia in 2007 (5) and in French Polynesia
and other South Pacific islands in 2013 and 2014 (6, 7). The virus was subsequently
detected for the first time in Brazil in 2015 (8), causing infections in epidemic propor-
tions, and spread rapidly to many countries in the Americas and other parts of the
world. The virus exists as two major lineages, African and Asian (2, 9, 10). Sequence
analyses have revealed that the Asian lineage ZIKV is responsible for the recent
outbreaks (4, 10). Typically, the majority of ZIKV infections in humans are asymptomatic,
but approximately 20% of the infections are associated with mild, self-limiting symp-
toms of flu-like febrile illness that are resolved within days. However, the most alarming
observations from the recent outbreaks were the increased incidences of Guillain-Barré
syndrome (GBS), an immune system-mediated autoimmune disease of the peripheral
nervous system, and congenital malformations, including microcephaly, fetal growth
restriction, and other disorders that have been collectively termed congenital ZIKV
syndrome (CZS) (3, 4, 11–13).
ZIKV is a mosquito-transmitted flavivirus in the family Flaviviridae. Its 10.8-kb
positive-sense RNA genome encodes a single polyprotein that is processed by viral and
host proteases to generate three structural (capsid [C], premembrane [prM], and
envelope[E]) and seven nonstructural (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5)
proteins. Like those of closely related flaviviruses, such as dengue (DENV), West Nile
(WNV), yellow fever (YFV), and Japanese encephalitis (JEV) viruses, the structural
proteins are involved in virion formation, attachment, and entry into host cells (14),
whereas the nonstructural proteins participate in genome replication, virion assembly,
and evasion of host antiviral responses (15–17). The recent expansion of the geographic
range and the severity of the virus-induced diseases in humans suggest genetic
evolution of ZIKV (2, 9, 18–21). Adaptive evolution resulting from accumulation of
genetic changes and/or stochastic introduction of the virus into large naive human
populations have been proposed to account for ZIKV emergence with pathogenic
potential (2, 4, 18, 22). Comparative genomic and phylogenetic analyses have identified
amino acid substitutions (18, 21, 23) that may contribute to the increased rate of
transmission and/or pathogenicity. However, formal investigation of the genetic
changes that are responsible for the pathogenic traits of the virus is currently lacking.
Only one recent study shows that the enhanced infectivity of ZIKV in the Aedes aegypti
mosquito vector resulting from a mutation in the NS1 protein could potentially
facilitate transmission and contribute to the spread of the virus from Asia to the
Americas (24).
In the present study, we developed a reverse genetic system for ZIKV to address the
role of a specific sequence motif, 153VNDT156, containing an N-linked glycosylation
site (underlined) within the E protein, in pathogenic properties of the virus. The VNDT
motif is absent in many of the African ZIKV isolates but present in all isolates from the
recent outbreaks (20) and may play a critical role in viral pathogenicity. By genetic
manipulation of the viral genome, we recovered mutant ZIKVs either lacking the VNDT
motif or with a single amino acid substitution (N154A) in the glycosylation site and
showed that the mutant viruses are highly attenuated in their ability to cause morbidity
and mortality in the mouse model and are compromised for neuroinvasion. Our results
provide evidence for a critical role of N-linked glycosylation of the E protein in ZIKV
virulence and neuroinvasion.
RESULTS
Infectious-clone-derived ZIKV mimics the in vitro growth and in vivo patho-
genic attributes of the parental virus. We sought to establish a reverse genetics
system for ZIKV by constructing a full-length cDNA clone of the strain MR766 virus (here
called MR). Four cDNA fragments (A to D) (Fig. 1A) spanning the entire viral genome
were amplified by reverse transcription (RT)-PCR and initially cloned in the pBR322
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vector. We consistently observed deletion of 1 or 2 nucleotides at positions around
2800 or 3500 in fragment A (within the NS1 coding region) of all (about 20) examined
clones. Attempts to repair the deletion at one site resulted in deletion at the other site,
indicating sequence instability around this region, as has been reported (25, 26).
Strategies such as insertion of introns into the viral genome (25, 26) or maintaining the
genome in multiple small fragments (27–31) have been used to overcome the inherent
instability of the ZIKV and other flavivirus genomes. Here, using a novel linear vector
FIG 1 Construction of an infectious clone of ZIKV MR766 and recovery and characterization of the clone-derived virus. (A) The viral genome with the encoded
proteins is shown at the top. The solid circle at the 5= end represents the cap. The genomic RNA from purified virions was amplified by RT-PCR with specific
primers to generate four cDNA fragments (A, B, C, and D), which were assembled into a full-length clone using naturally occurring restriction enzyme sites
shown above the fragments. The green rectangular box immediately upstream of fragment A represents the bacteriophage T7 RNA polymerase promoter (10).
A unique BssHII site was incorporated immediately following the viral sequences in fragment D to linearize the plasmid prior to in vitro transcription. The blue
lines on the left and right sides of the boxed regions represent sequences from pBR322. The entire genome, along with some sequence of pBR322 released
by digestion with ScaI and NruI, was cloned in the pJAZZ-OC linear vector (bottom) at the unique SmaI site in the multiple cloning site of the vector. telL and
telR, left and right telomeric sequence from coliphage N15; TelN, protelomerase gene of coliphage N15; repA, replication factor gene and origin of replication
of coliphage N15; cB, repressor protein of coliphage N15; Camr, chloramphenicol resistance gene. The approximate positions of transcriptional terminators, T1
(T7 early transcription terminator), T2 (transcription terminator from the E. coli rrnB gene), and T3 (bidirectional E. coli tonB-P14 transcription terminator) are
shown. The arrows indicate the direction of the coding sequence for repA and Camr. (B) In vitro transcripts from a full-length infectious clone (pJ-rMR) or from
a clone encoding the catalytically inactive polymerase (pJ-rMR/Pol) were transfected into Vero cells, and after 4 days, the cells were fixed and examined by
immunofluorescent staining for E protein using 4G2 antibody. Mock, cells treated with the transfection reagent only. The top row shows phase-contrast images;
the bottom row shows immunofluorescent images. (C) Infectious virus recovered from the transfected Vero cells at various days posttransfection as determined
by plaque assay on Vero cells. The dashed line represents the limit of detection. (D) Silent nucleotide substitutions (shown in red) were introduced into rMR
sequences as genetic tags, resulting in elimination of Bsu36I naturally present in the pMR and creation of AatII and BspEI sites in the rMR. The numbers on the
left and right of the sequences are the nucleotide positions in the viral genome. Amino acid residues encoded by these sequences (in blue) are shown in the
middle. (E) Confirmation of the presence of the genetic tag. A 1,822-bp DNA fragment was amplified by RT-PCR using the genomic RNA from the pMR or rMR
virus and primers (Table 2) and digested with the restriction enzymes shown. Upon digestion of the PCR-amplified product with Bsu36I or AatII, two DNA
fragments of 1,112 bp and 710 bp were generated. (F) Multistep growth of the pMR and rMR viruses in Vero and C6/36 cell lines. The graphs show mean values
with error bars representing SD from three independent experiments. An unpaired Student t test (two-tailed) was used to determine significance. ns,
nonsignificant.
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(32) (Fig. 1A) with bacterial transcription terminators flanking the cloning site, we
generated stable full-length cDNA clones of the ZIKV genome. When transfected into
Vero cells, in vitro transcripts from a full-length cDNA clone with correct sequence
(pJ-rMR) resulted in specific detection of E protein, whereas no such signal was
detected in cells transfected with RNA from a construct encoding an inactive polymer-
ase (pJ-rMR/Pol; GDD¡AAA mutation in NS5) (Fig. 1B). The transfected cells produced
infectious ZIKV with a maximum titer at 5 days posttransfection (Fig. 1C). After at least
10 successive passages of the plasmid (extraction and retransformation) in bacterial
culture, the plasmid was found to be stable and maintained the viral sequences, leading
to recovery of infectious virus (data not shown).
To distinguish the infectious-clone-derived recombinant MR virus (rMR) from the
parental MR virus (pMR), we had introduced four silent nucleotide substitutions,
resulting in the elimination of a naturally occurring Bsu36I site and creation of new AatII
and BspEI sites (Fig. 1D). We confirmed that the AatII site was present in the rMR but
not in the pMR, whereas the Bsu36I site was present in the pMR but not in the rMR (Fig.
1E). The rMR grew to similar or slightly (but not significantly) lower titers than the pMR
in Vero and C6/36 cell lines (Fig. 1F), suggesting that the infectious-clone-derived virus
exhibits growth kinetics similar to those of the pMR.
We next examined the in vivo pathogenic attributes of the rMR compared to the
pMR. Several mouse models have been established to study ZIKV pathogenesis in
immunocompetent, as well as immunodeficient, animals (for a review, see reference
33). Immunodeficient mice lacking the type I interferon (IFN) signaling pathways are
highly susceptible to ZIKV infection (34–39). A129 mice genetically lacking the IFN-/
receptor undergo significant body weight loss, show clinical disease with limb paralysis,
and succumb to infection. Using this model, following subcutaneous (s.c.) inoculation,
mice infected with the pMR or the rMR began to exhibit body weight loss 4 days
postinfection (dpi). The infected mice continued to lose weight, and at 6 dpi, weight
loss was significantly higher (Fig. 2A). One or two mice from each infected group died
at 6 dpi, whereas all the mice either died or were moribund and euthanized at 7 dpi
(Fig. 2B). The weight loss or survival of mice infected with the pMR or the rMR were
similar. The viral genome copy numbers in the plasma of animals infected with the rMR
were lower than in those infected with the pMR at 3 dpi but were comparable at 4 to
6 dpi (Fig. 2C). Infectious virus titers in the plasma at 3 dpi or 6 dpi were slightly lower
but statistically nonsignificant for the two groups of infected animals (Fig. 2D), indi-
cating that the clone-derived virus exhibited similar in vivo growth kinetics during the
infection period examined. Infectious-virus titers in tissues such as brain, spleen, or liver
at 6 dpi were also not significantly different between the two groups (Fig. 2E). Overall,
the results suggest that the rMR recapitulates the growth and pathogenic properties of
the pMR.
ZIKVs encoding nonglycosylated E protein exhibit growth properties similar to
those of the virus with the glycosylated protein. We examined available sequences
(n  330) of the E protein of ZIKV in GenBank, and four major types of polymorphism
were noteworthy (Table 1) around the sequence VNDT. Several African isolates of the
virus lack or have mutations in the VNDT motif, whereas the vast majority of the Asian
and all American isolates contain the motif (20). Furthermore, the MR virus also exhibits
polymorphism in the sequences around the VNDT motif. Because of the lack of detailed
knowledge on the passage history of the MR virus, it is unclear how the polymorphism
developed in this prototypic ZIKV over time. The motif, located in a loop, which we refer
to as the “glycan loop” (residues 146-SQHSGMIVNDTGHETDE-162), is in close proximity
to the E protein dimer interface and the fusion loop (40) of the adjacent E protein (Fig.
3A). The glycan loop, which is located in domain I (D-I) of the E protein (40), is 6 to 9
amino acids longer in ZIKVs than in several (but not all) other flaviviruses. Glycosylation
at the N154 site in ZIKV E protein has been proposed to play an important role(s) in
virus growth, pathogenicity, or disease severity (41), although experimental evidence
supporting this contention is lacking at this time. In related flaviviruses, this modifica-
tion was found to influence virus growth, stability, and virulence (42–46).
Annamalai et al. Journal of Virology
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To examine the roles of this motif and N-linked glycosylation, we generated mutant
viruses by either deleting the VNDT motif (m1MR) or generating a single-amino-acid
substitution mutant (m2MR) by altering the asparagine to alanine in the glycosylation
site. The sequences of the E proteins of these mutant viruses compared to that of the
wild-type (wt) virus (rMR) around this site are shown in Fig. 3B. The E protein synthe-
sized in m1MR- or m2MR-infected cells was not glycosylated, since it was not digested
by endo--N-acetylglucosaminidase H (endo H) or peptide-N-glycosidase F (PNGase F),
whereas it was glycosylated in rMR-infected cells (Fig. 3C). The mutant viruses grew to
FIG 2 Pathogenic properties of the pMR and rMR viruses in mice. (A and B) Weight loss and mortality of A129 mice inoculated s.c. with 1,000 PFU of the pMR
(n  6) or rMR (n  6) virus. PBS (n  5) was used as a negative control. (C) Genome copies in the plasma of animals described in panels A and B at 3, 4, 5,
and 6 dpi. (D) Plasma from blood collected at 3 dpi or 6 dpi from pMR- or rMR-inoculated mice was quantitated for infectious virus. (E) Infectious-virus loads
in the brain, spleen, and liver in mice inoculated with the pMR or the rMR. Two-way ANOVA (Tukey’s multiple-comparison test) (A), multiple t tests (C and D),
and an unpaired Student’s t test, two tailed (E) were used to determine significance. ****, P  0.0001; *, P  0.05; ns, nonsignificant.
TABLE 1 Amino acid sequence polymorphism around the VNDT motif in ZIKV isolates
Type Polymorphism(s)
Sequence
(148–162)a
No. with
polymorphism/total
African Asian American
I ΔVNDT HSGMI....GHETDE 5/61 0/41 0/228
II ΔIVNDT, ΔTGHETD, ΔTGHETDE HSGM........TDE 8/61 1/41 0/228
III VNDI HSGMIVNDIGHETDE 24/61 2/41 0/228
IV VNDT HSGMIVNDTGHETDE 24/61 38/41 184/228b
aOf the total number of sequences (n  330) examined, 264 were from full-length genomes and 66 from
partial E-coding sequences currently available in GenBank. The African sequences represented 17 full-length
genomes and 44 partial E sequences; Asian sequences represented 32 full-length genomes and 9 partial E
sequences; American sequences represented 215 full-length genomes and 13 partial E sequences. Amino
acid sequences from 148 to 162 of E are shown. VNDT is in bold-face with the glycosylation site underlined.
The periods represent sequence not present in the isolates.
bForty-four sequences from the American isolates had incomplete sequence information.
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slightly (but not statistically significantly) lower titers than the rMR in Vero cells and
C6/36 cells (Fig. 3D). Additionally, the glycan-deficient mutant viruses grew to titers
similar to those of the rMR virus in at least three other cell lines (HTR-8, a human
trophoblast cell line; NTERA-2, a human testicular cell line; and SH-SY5Y, a human
neuroblastoma cell line) that are the targets of ZIKV infection in humans (data not
shown). These results indicate that the deletion of the VNDT motif or the loss of a
glycosylation site in the E protein does not adversely affect in vitro growth of the
mutant viruses. The mutant viruses were also found to be stable following multiple
passages in Vero and C6/36 cells (data not shown).
The glycosylation mutant ZIKVs are attenuated in vivo. To elucidate the influ-
ence of glycosylation of the E protein on ZIKV pathogenicity, A129 mice were inocu-
lated s.c. with the rMR, m1MR, or m2MR virus. The rMR-infected mice began to show
signs of illness and weight loss at 4 dpi. All the mice in this group showed enhanced
clinical symptoms and by 6 dpi exhibited significantly high overall clinical scores (Fig.
4A) and weight loss (Fig. 4B). The mice were either moribund and euthanized for tissue
sample collection at 6 dpi or succumbed to infection at 7 dpi (Fig. 4C). In contrast, none
of the m1MR- or m2MR-infected mice exhibited clinical symptoms, and they appeared
healthy at 6 dpi (Fig. 4A). The m1MR-infected mice showed slight weight loss at 7 dpi
but began to gain weight after that (Fig. 4B), whereas m2MR-infected mice did not
exhibit body weight loss. All the animals except one (dead at 8 dpi) in the m1MR-
infected group appeared healthy at 8 dpi. A number of randomly chosen animals from
the m1MR- and m2MR-infected groups were also sacrificed at 6 dpi to examine virus
replication in tissues. About 25% of the remaining mice in the m1MR-infected group
FIG 3 Characterization of the mutant viruses lacking the glycosylation site in the E protein. (A) Three-dimensional structure of dimeric E protein of ZIKV (Protein
Data Bank [PDB] code 5IRE). The boxed region in the top diagram is enlarged below, showing the glycan moiety, glycan loop, fusion loop, and dimer interface.
(B) Amino acid sequence of the rMR and the mutant (m1MR and m2MR) viruses around the VNDT motif. (C) Examination of the glycosylation status of the E
protein in cells infected with the rMR, m1MR, or m2MR virus. Vero cells infected with the viruses (MOI  1) were radiolabeled with Expre35S35S protein-labeling
mix, immunoprecipitated with 4G2 antibody, digested with endo H or PNGase F, analyzed by SDS-PAGE, and detected by fluorography. Relative migration of
molecular mass markers (in kilodaltons) is shown on the left. (D) Multistep growth of the rMR, m1MR, and m2MR in Vero and C6/36 cells. The graphs show mean
values, with error bars representing standard deviations from the results of three independent experiments. An unpaired Student t test (two-tailed) was used
to determine significance. ns, nonsignificant.
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began showing paralysis of one or both hind limbs at 9 dpi, but interestingly, a majority
of them recovered within 2 days. Importantly, over 75% of the m1MR-infected animals
did not show any clinical symptoms for prolonged periods of up to 2 months, when the
animals were eventually euthanized. Likewise, none of the animals in the m2MR-
infected group showed any clinical symptoms for up to 2 weeks of observation.
Viral-genome copy numbers in the plasma were higher for rMR-infected animals at 3 to
5 dpi than those in m1MR- or m2MR-infected animals but were not significantly
different for all three groups at 6 dpi (Fig. 4D). Since the m1MR and m2MR viruses
replicated to slightly lower titers under in vitro growth conditions (Fig. 3D), it is possible
that the diminished viral load in the plasma of the mutant-virus-infected animals at 3
to 5 dpi could be due to their lower replication potential compared to the rMR. It
should be noted that the viral-genome copy numbers in the plasma of m1MR- and
m2MR-infected animals were not significantly different from each other at various times
examined, indicating that both the mutant viruses replicated to nearly similar levels in
the animals. The infectious-virus loads in the plasma of the infected animals in the three
groups showed a trend at 3 and 6 dpi similar to that of the genome copy numbers (Fig.
4E). The viral loads in the plasma of m1MR- or m2MR-infected animals were reduced
significantly at 7, 10, and 14 dpi compared to 6 dpi (data not shown). These results
FIG 4 Mutant viruses are attenuated in mice. (A) Clinical scores at 6 dpi in A129 mice inoculated s.c. with 1,000 PFU of the rMR (n  8), m1MR (n  8), or m2MR
(n  6) virus. See Materials and Methods for clinical symptoms and scores. (B and C) Weight loss and mortality of A129 mice inoculated s.c. with 1,000 PFU
of the rMR (n  13), m1MR (n  23), or m2MR (n  12) virus. PBS (n  6) was used as a negative control. (D and E) Viral-RNA copies and infectious-virus titers
in the plasma of infected animals at various times postinfection. The data presented in panels B to E are combined data from two independent experiments.
Unpaired Student t tests, two-tailed (A) and multiple t tests (D and E) were used to determine significance. ****, P  0.0001; ***, P  0.001; ns, nonsignificant.
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suggest that the mutant ZIKVs with the deletion of the VNDT motif or lacking the
glycan moiety on the E protein were attenuated, as their ability to cause disease and
lethality was markedly diminished.
Replication of the glycosylation mutant ZIKVs is severely restricted in the brain
but not in the spleen or liver in infected animals. To understand pathogenic
differences between the rMR and the mutant ZIKVs, we examined tissues of the
infected animals collected at 6 dpi. Histopathological examination of brain sections
revealed specific differences between the groups. rMR-infected animals showed mod-
erate to severe lesions in the meninges and moderate inflammation in the brain
compared to those infected with m1MR or m2MR virus (data not shown). Diffuse
lymphocytic infiltrates in the meninges and scattered dark hyperchromatic neurons
were prominent in the brain sections from rMR-infected but not m1MR- or m2MR-
infected animals (Fig. 5i, iv, and vii). There were mild to moderate levels of karyorrhexic
debris and lymphocytic cuffing in the brains of rMR-infected animals but minimal brain
inflammation or neuronal pathology in m1MR- or m2MR-infected animals (Fig. 5ii, v,
and viii). Interestingly, the spleens of m1MR- or m2MR-infected mice showed signifi-
FIG 5 Histopathological examination of tissues of animals infected with the wt or mutant virus. H&E staining of sections of brains (meninges and
cerebrum) and spleens of animals infected with the rMR, m1MR, or m2MR virus is shown. Representative images from the experiment are shown.
Bars, 60 m in meninges and cerebrum, 30 m in spleen.
Annamalai et al. Journal of Virology
December 2017 Volume 91 Issue 23 e01348-17 jvi.asm.org 8
cantly higher lymphoid hyperplasia than those of rMR-infected animals (Fig. 5iii, vi, and
ix). The rMR-infected group had moderate neutrophil infiltrates throughout the spleen
that were absent in the mutant-virus-infected groups (Fig. 5iii, vi, and ix). The histo-
logical presentations of livers and kidneys in all three groups of animals were similar.
To determine if the histopathological differences were due to the differences in the
levels of replication of the wt and mutant viruses, we examined the viral loads in tissues
of the animals. Indeed, the rMR replicated in the brains of infected animals robustly, and
both numbers of genome copies (Fig. 6A) and levels of infectious virus (Fig. 6B) were
significantly higher than those from m1MR- or m2MR-infected animals. Both m1MR and
m2MR viruses replicated poorly in the brain at this time. The genome copies and
infectious virus titers were about 750- to 1,500-fold and 5,000- to 8,000-fold, respec-
tively, lower than those from the rMR-infected group (Fig. 6A and B). The levels of
infectious virus in the spleen were similar among the three groups but were somewhat
lower in the livers of the m1MR- and m2MR-infected groups than in those of the
rMR-infected group (Fig. 6C). The results suggest that the presence and/or replication
of the mutant viruses in the brain is severely restricted.
FIG 6 The mutant viruses replicate less efficiently in the brains of infected animals. (A and B) Viral-
genome copy numbers (A) and infectious-virus titers (B) in the brains of animals infected with the rMR
(n  8), m1MR (n  8), and m2MR (n  8) viruses at 6 dpi. (C) Infectious-virus titers in the spleens and
livers of animals infected with the rMR, m1MR, and m2MR viruses at 6 dpi. Data from two separate
experiments were combined. An unpaired Student t test (two-tailed) was used to determine significance.
****, P  0.0001; ns, nonsignificant.
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The glycosylation mutant ZIKVs are defective in neuroinvasion. It is possible
that the mutant ZIKVs are either defective in neurotropism or compromised for
neuroinvasion when inoculated by the parenteral route (s.c.). To examine this, we
inoculated mice with the viruses intracranially (i.c.). This allowed us to bypass the
blood-brain barrier (BBB) and examine viral replication and pathology independently of
neuroinvasive factors. Following i.c. inoculation, the mice in all three groups appeared
healthy for the first 3 days but began to lose weight and show signs of illness at 4 dpi.
This was in stark contrast to s.c. inoculation with the mutant ZIKVs, where none of the
animals showed any sign of illness. Control mice inoculated with phosphate-buffered
saline (PBS) alone did not exhibit any body weight loss or illness. Numbers of viral-
genome copies in the plasma at 4 dpi and 5 dpi were higher in the rMR-infected group
than in the mutant-virus-infected groups (data not shown), similar to what was
observed in s.c. inoculation (Fig. 4D). However, when mice were sacrificed at 6 dpi and
tissues were examined, the numbers of genome copies and infectious-virus titers in the
mutant-ZIKV-infected groups were significantly higher in the brain (Fig. 7A and B) than
those from mice inoculated s.c. with the mutant viruses (Fig. 6A and B). Numbers of
genome copies in the brains of the mutant-virus-infected animals inoculated i.c. were
FIG 7 Mutant viruses replicate well in the brain when inoculated i.c. Mice were inoculated i.c. with 1,000
PFU of the rMR (n  5), m1MR (n  5), or m2MR (n  5) virus. (A and B) RNA copies (A) and infectious
virus (B) in brains of animals at 6 dpi. (C) Infectious virus in spleens and livers of the same animals at 6
dpi. An unpaired Student t test (two-tailed) was used to determine significance. *, P  0.05; ns,
nonsignificant.
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about 50- to 80-fold higher than in those inoculated s.c. (1.18  1010/g versus 1.39 
108/g for m1MR virus and 1.3  1010/g versus 2.7  108/g for m2MR virus), whereas
numbers of PFU were nearly 80- to 100-fold higher (4.2  105/g versus 4.5  103/g for
m1MR and 5.4 105/g versus 6.8 103/g for m2MR virus). The rMR replicated well and
to similar levels in the brains of animals inoculated by the two routes. The levels of
infectious virus in the spleen were similar between the rMR-infected and the mutant-
virus-infected groups but were slightly lower in the liver (Fig. 7C). Furthermore, the
levels of replication of the rMR or the mutant viruses in the spleen and liver were similar
when inoculated by either route (Fig. 6C and 7C). Lymphocytic meningitis and enceph-
alitis were evident and of comparable severity in all three groups of i.c.-inoculated mice.
Mild to moderate lymphoid hyperplasia in the spleen was also observed among the
three infected groups. The i.c.-inoculated rMR group was associated with moderate
neutrophils in the spleen, similar to the s.c. challenge group, whereas neutrophils were
rare in the spleens of the mutant-virus-infected mice inoculated by either route. These
studies suggest that the mutant viruses replicate well in the brain when inoculated i.c.
but may be compromised in their ability to invade the brain from the peripheral site,
as seen with s.c. inoculation.
DISCUSSION
With the unprecedented emergence of ZIKV causing diseases, including GBS, mi-
crocephaly, and CZS (3, 4, 11–13), attention has focused not only on developing
intervention strategies to combat ZIKV diseases, but also on understanding the mech-
anisms of the virus’ emergence and what genetic changes may have contributed to its
sudden widespread dissemination and enhanced pathogenicity. Comprehensive ge-
netic, phylogenetic, and evolutionary studies on ZIKV isolates before and during the
epidemic have suggested amino acid substitutions in the structural and NS proteins
that may contribute to virus transmission, efficient replication, and/or neurotropism (2,
20, 21, 23). In fact, a recent study has shown that a single amino acid substitution
(A188V) in the viral NS1 protein is critical for NS1 antigenemia, which in turn facilitates
ZIKV acquisition by mosquitoes from viremic animals (24). With the availability of
infectious clones of ZIKV (25-29, 47) from historical and contemporary isolates, it will be
possible to further examine the specific changes in the viral genome that are respon-
sible for viral transmission, replication, virulence, and tissue tropism.
Here, we investigated the role of the VNDT motif, as well as glycosylation within the
motif in the E protein, which appears to exhibit polymorphism in ZIKV isolates. This
sequence is located in a loop region in close proximity to the fusion loop as well as the
dimer interface, and therefore, glycosylation at this site may impact virus growth,
immune evasion, transmission, and/or virulence. VNDT is present in all isolates from the
recent outbreaks and absent in several of the African isolates (2, 20) (Table 1), suggest-
ing its potential role in pathogenicity. Additionally, the original African MR766 virus
exhibits polymorphism at this site, which could be due to the growth of the virus in the
host species from which it was isolated or to the passage of the virus in culture, or both.
Given that the passage histories of some of the MR766 isolates whose sequences have
been reported in GenBank are unknown, it is unclear how the polymorphism at this site
developed. The passage history and animal species from which the virus is isolated
could result in deletions, insertions, and/or amino acid substitutions at critical sites in
the viral sequences, resulting in polymorphism at those sites, and could potentially lead
to increased or decreased transmissibility and pathogenicity. We set out to examine if
N-linked glycosylation within the VNDT motif plays any role in ZIKV pathogenicity in an
immunocompromised-mouse model. Although infectious clones of MR766 viruses (25,
28, 29), as well as several other ZIKV isolates (26, 27, 47), have been reported, the role
of VNDT or glycosylation in this region in pathogenicity has not been explored. A recent
study using ectopic expression and pseudoparticle formation with a WNV replicon
showed that N-glycosylation of ZIKV E protein is necessary for efficient particle assem-
bly and infectivity (48). The results reported here provide evidence that the deletion of
the VNDT motif or a single amino acid substitution within the glycosylation site
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resulting in the loss of N-glycosylation of the E protein did not significantly affect in
vitro or in vivo growth of the virus; however, the pathogenicity of the mutant viruses
was significantly compromised.
Studies with WNV have shown that E protein glycosylation influences particle
assembly and infectivity (44), as well as neuroinvasion (43, 46). The results presented
here suggest glycosylation of E is an important determinant of ZIKV virulence and
neuroinvasion. The data also support the contention that the mutant ZIKVs lacking the
glycan cannot breach the BBB and neuroinvade as efficiently as the wt virus. The
mechanism(s) by which ZIKV enters the CNS from peripheral sites of inoculation is not
known, but it likely does so by disrupting the BBB, which is thought to be a key intrinsic
defense against encephalitic viruses (49). The BBB consists of brain microvasculature
endothelial cells with specialized tight junctions. One possibility is that ZIKV gains
central nervous system (CNS) access either as cell-free virus or through infected blood
monocytes, which circumvent the BBB. Alternatively, ZIKV may directly infect the
endothelial cells or choroid plexus epithelial cells, disrupt the BBB, and enter the CNS.
Since the TAM receptor AXL makes endothelial cells susceptible to ZIKV infection
(50–52), access of the mutant ZIKVs encoding nonglycosylated E protein to the CNS
might be compromised due to their inability to infect these cells. Since WNV disrupts
expression of or signaling by IFN- (53) and also uses the Toll-like receptor 3-dependent
immune response (54) to gain entry into the CNS, it is possible that ZIKV may employ
similar or yet unknown mechanisms to facilitate its entry into the CNS. The mutant
ZIKVs may have lost their ability do so. Nevertheless, studies to identify the mecha-
nism(s) by which ZIKV gains entry into the CNS will be important to understand how
the mutant viruses are unable to neuroinvade.
The reason(s) for the death of one animal in the m1MR-infected group is unknown
but could be due to excessive weight loss by the animal, which impacted the overall
weight loss on day 7 in this group (Fig. 4B). It is possible that the mutant virus may have
reverted to a virulent phenotype in this particular animal. Future studies examining if
the mutant virus reverts to a virulent phenotype in some animals through acquisition
of compensatory mutations may shed light on this relatively rare event. Some of the
animals infected with the mutant ZIKVs developed transient hind limb paralysis that
resolved within days. At this time, the cause of the paralysis and the rapid recovery from
the disease is unknown. However, it would be interesting to examine if there is a strong
immune response directed against the antigens of Schwann cells, leading to paralysis.
The presence of prominent hyperplastic germinal centers in the spleens of the mutant-
virus-infected mice suggests robust antibody responses. It is possible that these mice
have high overall immunoglobulin levels, some of which may be directed toward
Schwann cells, thus causing the paralysis. Whether the paralysis observed in the mice
represents a form of GBS seen in some ZIKV-infected humans remains to be investi-
gated. Since the rMR-infected mice succumbed to infection by 7 dpi (before the onset
of paralysis), further studies would be necessary to determine whether these mice
would have displayed paralysis had they survived longer. In conclusion, our studies
presented here suggest that E protein glycosylation is an important determinant of
ZIKV pathogenicity and neuroinvasion.
MATERIALS AND METHODS
Ethics statement. All procedures involving animals were conducted in accordance with the guide-
lines established in the Guide for Care and Use of Laboratory Animals of the National Institutes of Health.
The protocol was approved by the Institutional Animal Care and Use Committee at the University of
Nebraska—Lincoln (UNL). The animals were housed in the Life Sciences Annex building at the university.
Mice were anesthetized with isoflurane prior to inoculation, and all efforts were made to minimize animal
suffering.
Cells, viruses, and reagents. Vero (Cercopithecus aethiops; CCL-81), C6/36 (Aedes albopictus; CRL-
1660), SH-SY5Y human neuroblastoma (CRL-2266), HTR-8/SVneo human trophoblast (CRL-3271), and
NTERA-2 human embryonal carcinoma (CRL-1973) cells were obtained from the ATCC. The cells were
grown and maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% heat-inactivated
fetal bovine serum (FBS) and penicillin-streptomycin (PS) in a humidified chamber with 5% CO2 at 37°C,
except C6/36 cells, which were maintained at 32°C.
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The MR766 strain of ZIKV was obtained from Barbara Johnson at the Centers for Disease Control and
Prevention, Fort Collins, CO, USA. We passaged the virus once in Vero cells to prepare a stock of the virus,
from which genomic RNA was extracted for construction of the infectious clone. Upon sequencing of
some protein-coding regions of the genome, we determined that the virus sequence corresponded to
GenBank accession number KU720415. For preparation of the stock virus, Vero cells were infected with
MR766 virus at a multiplicity of infection (MOI) of 0.1 PFU per cell. Following adsorption at 37°C for 1 h,
the inoculum was removed and replaced with virus growth medium (VGM) (DMEM containing 2% FBS,
PS, 20 mM HEPES, 1 mM sodium pyruvate, and nonessential amino acids). The infected cells were
incubated at 37°C for 4 days, after which the culture supernatant was collected and clarified, FBS was
added to a final concentration of 20%, and the stock virus was stored in small aliquots at 80°C. For
multistep growth analysis, cells were infected at an MOI of 0.1 PFU/cell and incubated as described
above. Small aliquots of infected cell culture supernatants were collected at various times postinfection,
clarified, and stored at 80°C for virus titration at a later time. Virus quantitation was performed by
plaque assay on Vero cells. Duplicates of serial 10-fold dilutions of virus in VGM were applied to Vero cell
monolayers in 24-well plates. Following virus adsorption, the inoculum was removed, and the cell
monolayers were overlaid with medium containing 1% low-gelling-temperature (LGT) agarose in VGM.
After incubation for 5 days at 37°C, the cells were fixed in 10% formaldehyde in PBS for 30 min, the
agarose plugs were removed, and the monolayers were stained with 0.1% crystal violet in 30% methanol.
Plaques were counted manually.
Restriction enzymes, DNA-modifying enzymes, the Q5 High Fidelity PCR kit, the ProtoScript II First
Strand cDNA synthesis kit, endo H, and PNGase F were obtained from New England BioLabs (Ipswich,
MA). SuperScript II was obtained from Invitrogen (Carlsbad, CA). Anti-flavivirus monoclonal antibody
D1-4G2-4-15, which reacts with ZIKV E protein, was obtained from EMD Millipore (Billerica, MA).
Secondary antibodies were obtained from Sigma (St. Louis, MO) and Invitrogen. TransIT-mRNA transfec-
tion reagent was obtained from Mirus Bio (Madison, WI). Oligonucleotide primers and probes for DNA
amplification and quantitative PCR (qPCR) were obtained from Sigma and IDT (Coralville, IA). The
mMessage mMachine T7 Ultra transcription kit was from Ambion (Austin, TX). Expre35S35S protein
labeling mix was obtained from PerkinElmer (Waltham, MA).
Construction of a full-length cDNA clone and virus recovery. Viral RNA extracted from culture
supernatants of infected Vero cells was used as the template for the generation of infectious clones. Four
cDNA fragments were amplified by RT-PCR using specific primers shown in Table 2. The amplified
products were digested with the appropriate restriction enzymes and cloned in a stepwise manner into
the pBR322 vector. Fragment A, which contained an AatII site along with a T7 RNA polymerase promoter
and one extra G nucleotide for efficient transcription initiation by the polymerase at the 5= end prior to
the beginning of the viral sequences and SbfI and NruI sites at the 3= end, was digested with AatII and
NruI and cloned into pBR322 at the same sites. Fragments B, C, and D were likewise cloned with the use
of unique restriction enzyme sites naturally present in the viral sequences, as well as additional sites
incorporated in the primers. The forward primer for amplification of fragment B contained several silent
mutations as genetic tags. Fragment D contained a unique BssHII site immediately following the viral
genome to linearize the plasmid for in vitro transcription. Since we detected deletion of one or two
nucleotides in fragment A at around nucleotide positions 2800 and 3500, we transferred the full-length
assembled clones from the pBR322 vector (by digestion with ScaI and NruI) into the linear plasmid
pJAZZ-OC (32) using the unique SmaI site in the multiple cloning region of the plasmid. The linear vector,
obtained from Lucigen Corporation (Middleton, WI, USA), employs transcription-free cloning technology
TABLE 2 Primers used in this study
Primer Sequence (5=–3=)a Purpose
1F cggatcgacgtcTAATACGACTCACTATAGAGTTGTTGATCTGTGTGAGTCAGACTGCG Amplification of fragment A
5030R gagccgtcgcgaGGATCGGAGATCCTGAGGTCCCTGCAGGGTAGT Amplification of fragment A
5003F ctctggactacCCTGCAGGGACGTCCGGAAGTCCGATCCTAGACAAATGTGG Amplification of fragment B
7190R catcattagcatcgcgaCTCCAAGGTCCCATGCATAAAATGG Amplification of fragment B
7006F CATTGATCTGCGGCCAGC Amplification of fragment C
8860R gttgattcgcgaTTCTTTGGTGCAGACGCGTGGCCGC Amplification of fragment C
8584F CCATGGGAGCTACGAAGC Amplification of fragment D
10807R gagacttcgcgagcgcgcAGAAACCATGGATTTCCCCACACCGGCCGCCGAAGTTCG
GCGATCTGTGCCTGGC
Amplification of fragment D
POL-6126F CCTCGCTCTATCGGCCTGAGGCCGATAAG Polymerase mutation
POL-9709R gacactCCTGAGGGCATGTGCAAACCTATCATCGATTGGCTTCACAACGCAGG
CAGCTGCACTGACCGCCATTCGTTTG
Polymerase mutation
PJAZZ-10222F GCCCACCCGAAGGTGAG Glycosylation mutation
GLY-1467R CTATTTTCGTCAGTTTCATATCCAATCATCCCGCTATGC VNDT deletion
N154A CAGTTTCATATCCTGTATCAGCGACAATCATCCCGCTATG Glycosylation mutation
GLY-3302R CTTCACTGTGCCATGGC Glycosylation mutation
Tag-3902F GCTCTTGAAGGTGACTTG Detection of genetic tag
Tag-5723R CATTTCCGTTTCTCACGC Detection of genetic tag
aRestriction enzyme sites are underlined. Viral sequences are shown in boldface uppercase letters. Lowercase lightface letters represent random nonspecific sequences
in the primers. Uppercase lightface letters represent a T7 RNA polymerase promoter sequence and an extra G (in primer 1F) and vector sequences (in primer
PJAZZ-10222F).
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due to the presence of multiple transcription terminators flanking the cloning site. This eliminates
transcription both into and out of the insert DNA and results in increased stability of the insert DNA in
the bacterial host. The important genetic and regulatory elements of the vector are described in the
legend to Fig. 1. The plasmid, which contains an inducible origin of replication from phage N15, can be
maintained at approximately 2 to 4 copies/cell in the BigEasy TSA host strain (Lucigen Corporation).
Further details of the BigEasy TSA host strain can be obtained from Lucigen Corporation or from the
corresponding author.
Following the transfer of the full-length ZIKV cDNA clone into the pJAZZ-OC vector, we repaired the
mutation(s) by fragment exchange using the unique AflII site at position 2993 of the viral genome. Stable
full-length clones (pJ-rMR) of correct sequences were recovered using this vector and used subsequently.
Fragment A was also subcloned in the linear vector, which was used as the template for mutagenesis to
generate the VNDT deletion mutant (m1MR) or the glycosylation mutant (m2MR) by substituting alanine
in place of asparagine using the primers (Table 2). A polymerase-defective full-length clone (pJ-rMR/Pol)
was generated using the primers (Table 2) with the full-length clone as the template.
In vitro transcription, RNA transfection, and virus recovery. An mMessage mMachine T7 Ultra
transcription kit from Ambion (Austin, TX) was used for in vitro synthesis of RNA from full-length clones
according to the manufacturer’s recommendations. Plasmids containing the full-length viral genomes
(rMR, Pol, or mutant constructs) were linearized by digestion with BssHII and then used for in vitro
transcription to generate full-length transcripts. Following digestion of the reaction products with RQ1
RNase-free DNase (Promega, Madison, WI, USA), the RNA was recovered and quantitated by spectrom-
etry, as well as by agarose gel electrophoresis. One to 5 g of RNA was transfected into monolayers of
Vero cells in six-well plates using TransIT-mRNA transfection reagent according to the manufacturer’s
recommendations. The transfected cells were incubated in a CO2 chamber at 37°C and observed for
development of cytopathic effects. Aliquots of the culture supernatants were collected at 24-h intervals
for plaque assay to determine if infectious virus was recovered from the transfected cells.
Mouse studies and pathogenesis evaluation. Four-week-old mice deficient in IFN-/ receptor
(A129) were obtained from the Jackson Laboratory, Bar Harbor, ME, USA. After acclimatization for 4 days,
the mice were anesthetized as described above and inoculated s.c. with 1,000 PFU of MR766 (pMR),
infectious clone-derived recombinant MR766 (rMR), VNDT deletion (m1MR), or glycosylation mutant
(m2MR) virus diluted in 100 l of PBS. For intracranial (i.c.) inoculation, 1,000 PFU of these viruses was
diluted in 30 l of PBS. Following virus inoculation, the mice were monitored twice daily for disease signs.
Weight change, clinical symptoms, and survival were recorded daily. Clinical symptoms were scored as
follows: 0, normal; 1, ruffled fur; 2, conjunctivitis, lethargy, and hunched posture; 3, paralysis of one hind
limb; 4, paralysis of both hind limbs; 5, paralysis of all four limbs; 6, moribund and euthanization; 7, dead.
Mice were scored as moribund when they appeared very lethargic, showed limb paralysis, and/or lost
greater than 20% of their initial body weight. Blood was collected by retro-orbital bleeding under
anesthesia. For tissue sample collection, mice were euthanized by CO2 inhalation.
Histopathological evaluation. Sections of brain, liver, spleen, and kidney were collected into 10%
neutral buffered formalin, processed routinely into paraffin wax, and sectioned at 5 m. The tissue
sections were then stained with hematoxylin and eosin (H&E) for histologic evaluation. The slides were
examined by a certified pathologist blinded to the treatment groups. Brain sections were evaluated for
meningitis, encephalitis, and neuronal necrosis. Spleens were evaluated for neutrophilic infiltrates,
lymphoid karyorrhexis, and follicular hyperplasia. Livers were scored for numbers of inflammatory-cell
foci. Any other findings deviating from normal tissues were noted. Severity was scored as follows: 0,
normal; 1, minimal; 2, mild; 3, moderate; and 4, severe. Meningoencephalitis scores were combined
meningeal and parenchymal scores.
Real-time qPCR. Mice were euthanized at 6 dpi to collect brain, spleen, and liver samples, with one
half used for qPCR and the other half used for H&E staining. Plasma recovered from blood collected at
various times postinfection was used for qPCR. All samples for quantitation of viral loads were stored
at 80°C until further processing. Tissue samples were weighed and homogenized in 1 DMEM in a
Bullet Blender (Next Advance, Inc., Averill Park, NY) using metal beads with the speed setting at 10 for
5 min at 4°C. Homogenized extracts were clarified by centrifugation at 14,000  g for 15 min at 4°C, and
the supernatants were used to perform plaque assays and viral RNA isolation. RNA isolation was
performed with a QIAamp viral-RNA extraction kit (Qiagen, Valencia, CA) using 140 l of tissue
homogenate or 10 to 20 l plasma. We employed a standard curve method for absolute quantification
of ZIKV RNA from the samples using a specific real-time qPCR assay. The primer and 6-carboxyfluorescein
(FAM) probe sequences were adopted from a published method (55) with in-house modification and
optimization. An oligonucleotide corresponding to the E gene sequence at positions 1191 to 1268 was
synthesized and used as the template for determination of a standard curve using the primers 5=-GTC
GTTGCCCAACACAAG-3= (forward) and 5=-CCACTAATGTTCTTTTGCAGAC-3= (reverse) and the probe 5=-
/56-FAM (5= 6-carboxyfluorescein)/AGCCTACCT/ZEN/TGACAAGCAATCAGACACTCAA/3IABkFQ (3= Iowa black
fluorescent quencher)/-3=. Real-time PCR assays were performed in two steps: viral RNA was used for
cDNA synthesis by SuperScript II (Thermo Fisher Scientific Inc., MA), and the cDNAs were then used as
the templates in qPCR. The cycling conditions used were as follows: initial denaturation at 95°C for 10
min; 35 cycles of 95°C for 30 s, 55.3°C for 30 s, and 72°C for 30 s; and a melt curve from 65°C to 95°C with
0.5°C increments for 5 s. The reactions were run in CFX Connect (Bio-Rad, CA). Viral-genome copy
numbers were determined in parallel reactions using RNA samples in duplicate and expressed as copy
numbers per gram of tissue or milliliter of plasma.
Immunofluorescence. For the detection of E protein following transfection with in vitro transcripts,
transfected cells were washed three times with cold PBS, fixed in cold methanol-acetone (1:1) for 10 min,
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and then washed with PBS three times. Primary antibody (4G2) targeting ZIKV E protein was added at a
1:500 dilution and incubated for 1 h at room temperature. The cells were washed three times with PBS,
and then Alexa Fluor 488-conjugated secondary antibody was added for 1 h in the dark. Following
incubation, the cells were washed three times with PBS and examined under a fluorescence microscope.
Images were obtained using the Evos FL Auto Cell Imaging System at the Microscopy Core Facility at
the UNL.
Metabolic radiolabeling and immunoprecipitation. Radiolabeling of viral proteins in infected cells
was performed with Expre35S35S protein-labeling mix as described previously (56). The radiolabeled E
protein from ZIKV-infected cells was immunoprecipitated with 4G2 antibody, digested with endo H or
PNGase F according to the manufacturer’s recommendations, examined by electrophoresis in an 8%
polyacrylamide gel containing sodium dodecyl sulfate (SDS-PAGE) under reducing conditions, and
detected by fluorography as described previously (56).
Statistical analysis. Data were analyzed using GraphPad Prism software version 6.0. An unpaired
two-tailed Student t test or Mann-Whitney test was performed for pairwise comparisons between the
groups to determine significant differences in viral loads (RNA levels and infectious titers). Percent weight
change between groups was analyzed by two-way analysis of variance (ANOVA) (Tukey multiple-
comparison test). The data are represented as either means and standard errors of the mean (SEM) or
means and standard deviations (SD).
Accession number(s). The sequence of the infectious clone reported here has been deposited in
GenBank with accession number KY989511.
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